- in Canada
- with readers working within the Banking & Credit and Healthcare industries
- within Real Estate and Construction topic(s)
On June 21, 2023, Xbrane announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Xbrane's supplemental Biologics License Application (sBLA) for a LUCENTIS® (ranibizumab) biosimilar candidate. Xbrane stated that "[t]he biosimilar candidate is a VEGF-a inhibitor, intended for the treatment of serious eye diseases such as wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion and myopic choroidal neovascularization." The biosimilar candidate was co-developed by Xbrane and STADA, and the two companies granted Bausch + Lomb an exclusive license to commercialize the biosimilar candidate in the United States and Canada.
There are currently two FDA-approved biosimilars to LUCENTIS®: Biogen and Samsung Bioepis's BYOOVIZ® (ranibizumab-nuna) and Coherus's CIMERLI® (ranibizumab-eqrn).
The FDA set a Biosimilar User Fee Amendment (BsUFA) goal date of April 21st, 2024.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
